VXRT - Vaxart May Be a COVID Vaccine Game Changer -- but Is It Too Late?
Vaxart (NASDAQ: VXRT) soared to stardom when its shares advanced 1,500% last year. Why the excitement?
The biotech company is developing a coronavirus-vaccine candidate in pill form. Investors realized such a product could win over those who cringe at the thought of needles.
But attention moved away from Vaxart after the first clinical-trial report. The candidate didn't produce neutralizing antibodies -- an element seen as key to blocking infection. Still, the investigational vaccine did boost immunity in other ways. And Vaxart continued along the development path.
For further details see:
Vaxart May Be a COVID Vaccine Game Changer -- but Is It Too Late?